Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy |
| |
| Authors: | Ute E Krainick-Strobel Werner Lichtenegger Diethelm Wallwiener Augustinus H Tulusan Fritz Jänicke Gunther Bastert Ludwig Kiesel Birgit Wackwitz Stefan Paepke |
| |
| Affiliation: | 1.Department of Obstetrics and Gynecology,University of Tübingen,Tübingen,Germany;2.Department of Obstetrics and Gynecology,Charité Medical University,Berlin,Germany;3.Department of Obstetrics and Gynecology,Klinikum Bayreuth,Bayreuth,Germany;4.Department of Gynecology,University Medical Center Hamburg-Eppendorf,Germany;5.Department of Obstetrics and Gynecology,University of Heidelberg,Germany;6.Department of Gynecology and Obstetrics,University of Münster,Germany;7.Novartis Pharma GmbH,Nürnberg,Germany;8.Women's Hospital, University Hospital Rechts der Isar,Technical University of Munich,Germany |
| |
| Abstract: | ![]()
Background In recent years, preoperative volume reduction of locally advanced breast cancers, resulting in higher rates of breast-conserving surgery (BCS), has become increasingly important also in postmenopausal women. Clinical interest has come to center on the third-generation nonsteroidal aromatase inhibitors (AIs), including letrozole, for such neoadjuvant endocrine treatment. This usually lasts 3–4 months and has been extended to up to 12 months, but optimal treatment duration has not been fully established. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
